PharmaShots Weekly Snapshots (April 01 – April 05, 2024)

Share this

PharmaShots Weekly Snapshots (April 01 – April 05, 2024)

This week PharmaShots’ news was all about the updates on Regulatory, Clinical Trials,Pharma, Pharma, Animal Health & MedTech. Check out our full report below:


The US FDA Approves Gilead’s Vemlidy 25mg Tablets for the Treatment of Chronic Hepatitis B Virus (HBV) Infection in Pediatric Patients

Read More: Gilead                                                  

The US FDA Approves AstraZeneca’s Voydeya as an Add-on Therapy to Treat Extravascular Haemolysis in PNH Patients

Read More: AstraZeneca                                       

The US FDA Grants ODD to Biostar Pharma’s Utidelone Injectable to Treat Breast Cancer Brain Metastasis

Read More: Biostar Pharma                                      

Fractyl Health’s IDE for Revita Receives the US FDA Approval for Conducting Remain-1 Study to Treat Obesity

Read More: Fractyl Health                                   

HUTCHMED and Innovent Report the NMPA’s NDA Acceptance for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

Read More: HUTCHMED                                       

The US FDA Accepts AstraZeneca and Daiichi Sankyo’s BLA of Datopotamab Deruxtecan (Dato-DXd) to Treat Breast Cancer

Read More:  AstraZeneca and Daiichi Sankyo’s       

The EMA Accepts Rocket Pharmaceuticals’ MAA of RP-L102 for Treating Fanconi Anemia

Read More:  Rocket Pharmaceuticals                       

The EC Expands Approval of BMS’ Reblozyl as a 1L Treatment of Transfusion-Dependent Anemia Due to Myelodysplastic Syndromes

Read More: BMS                                                        

Vanda Pharmaceuticals’ Fanapt Gains the US FDA’s Approval to Treat Bipolar I Disorder

Read More: Vanda Pharmaceuticals                                                   

The US FDA Accepts UCB’s sBLA of Bimzelx (bimekizumab-bkzx) for the Treatment of Hidradenitis Suppurativa

Read More: UCB                                                                        

Incyte and China Medical System Collaborate on Povorcitinib for Autoimmune and Inflammatory Dermatologic Indications

Read More: Incyte and China Medical System        

 Ipsen and Sutro Biopharma Join Forces on STRO-003 for Treating Solid Tumors

Read More: Ipsen and Sutro Biopharma                

MaxCyte Partners with Be Biopharma to Develop Engineered B Cell Medicines (BCMs)

Read More: MaxCyte                                               

Caris Life Sciences and Merck KGaA Join Forces to Discover and Develop ADCs for Cancer Treatment

Read More: Caris Life sciences and Merck               

MiNA Therapeutics and Nippon Shinyaku Partner on RNAa Therapeutics for Rare Neurodegenerative Diseases

Read More: MiNA Therapeutics and Nippon Shinyaku       

For an Aggregate of $1.8B, Genmab to Acquire ProfoundBio for Enhancing its Oncology Portfolio 

Read More: Genmab                                                    

ARCA Biopharma Merges with Oruka Therapeutics to Develop Biologics for Chronic Skin Diseases

Read More: ARCA & Oruka                                    

For an Aggregate of ~$13.1B, Johnson & Johnson to Acquire Shockwave Medical

Read More: Johnson & Johnson & Shockwave Medical                 

PassPort Technologies Reveals P-I Study Results of Zolmitriptan Transdermal Microporation System to Treat Acute Migraine

Read More: PassPort Technologies                      

The US FDA Clears Abbott’s Whole Blood Rapid Test for Evaluating Patients with Suspected Concussion 

Read More:  Abbott                                                     

The US FDA Approves Abbott’s Triclip Transcatheter Edge-To-Edge Repair System to Treat Tricuspid Regurgitation

Read More: Abbott                  

The US FDA Grants 510(k) Clearance to AngioDynamics’ AlphaVac F18⁸⁵ System for the Treatment of Pulmonary Embolism

Read More:Angiodynamics                  

 BMS Reveals the P-III (YELLOWSTONE) Trial Results of Zeposia for Treating Moderate to Severe Active Crohn’s Disease

Read More: BMS                                                      

EnteroBiotix Reports the Initiation of P-II Study Evaluating EBX-102-02 to Treat Irritable Bowel Syndrome (IBS)

Read More: EnteroBiotix                                                   

Merck and Daiichi Sankyo Dose First Patient with Raludotatug Deruxtecan in P-II/III (REJOICE-Ovarian01) Study to Treat Ovarian Cancer

Read More: Merck & Daiichi Sankyo                                                  

SpliSense Receives the US FDA’s Clearance for SPL84 P-II Clinical Evaluation to Treat Cystic Fibrosis

Read More: SpliSense                                                        

Neurocrine Biosciences Reports First Patient Dosing with NBI-1070770 Under the P-II Study to Treat Major Depressive Disorder

Read More: Neurocrine Bioscience                                                      

Merck Reports the Commencement of MK-1084’s P-III Study in Combination with Keytruda for Treating Metastatic Non-Small Cell Lung Cancer

Read More: Merck                                                                              

AstraZeneca Reports the P-III Study Results of Imfinzi for the Treatment of Small Cell Lung Cancer

Read More: AstraZeneca                                                                    

Teva Pharmaceuticals Partners with mAbxience to Develop Biosimilar Candidates for Treating Oncology Indications

Read More: Teva Pharmaceuticals                                                         

Related Post:- PharmaShots Weekly Snapshots (March 26 – March 29, 2024)

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions